Georgia Pines Community Service Board Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 3619 Jackson Dairy Rd, Baconton, GA 31716 Phone: 229-225-4335 Fax: 229-225-4374 |
News Archive
While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.
Hypoxia is a key factor that accompanies most brain pathologies, including ischemia and neurodegenerative diseases.
BioMarin Pharmaceutical Inc. today announced an update on the GALNS Phase 1/2 extension study (MOR-100) in which patients have continued treatment on an ongoing basis.
An examination of clinical practice guidelines for treating cardiovascular disease finds that current recommendations are largely based on lower levels of evidence or expert opinion, according to a study in the February 25 issue of JAMA, the Journal of the American Medical Association.
Researchers studying a new medication for neuropathic pain have reported intriguing findings about placebo response versus drug response from a Phase 2a proof-of-concept study. They presented their findings in a poster session at the 2011 International Conference on Accelerating the Development of Enhanced Pain Treatments.
› Verified 8 days ago